223 related articles for article (PubMed ID: 26647045)
1. Application of Low- and Mid-Frequency Raman Spectroscopy to Characterize the Amorphous-Crystalline Transformation of Indomethacin.
Larkin PJ; Wasylyk J; Raglione M
Appl Spectrosc; 2015 Nov; 69(11):1217-28. PubMed ID: 26647045
[TBL] [Abstract][Full Text] [Related]
2. Low- versus Mid-frequency Raman Spectroscopy for
Koskela J; Sutton JJ; Lipiäinen T; Gordon KC; Strachan CJ; Fraser-Miller SJ
Mol Pharm; 2022 Jul; 19(7):2316-2326. PubMed ID: 35503753
[TBL] [Abstract][Full Text] [Related]
3. Using the low-frequency Raman spectroscopy to analyze the crystallization of amorphous indomethacin.
Hédoux A; Paccou L; Guinet Y; Willart JF; Descamps M
Eur J Pharm Sci; 2009 Sep; 38(2):156-64. PubMed ID: 19591926
[TBL] [Abstract][Full Text] [Related]
4. Polymorph characterization of active pharmaceutical ingredients (APIs) using low-frequency Raman spectroscopy.
Larkin PJ; Dabros M; Sarsfield B; Chan E; Carriere JT; Smith BC
Appl Spectrosc; 2014; 68(7):758-76. PubMed ID: 25014842
[TBL] [Abstract][Full Text] [Related]
5. Low-frequency vibrational properties of crystalline and glassy indomethacin probed by terahertz time-domain spectroscopy and low-frequency Raman scattering.
Shibata T; Mori T; Kojima S
Spectrochim Acta A Mol Biomol Spectrosc; 2015; 150():207-11. PubMed ID: 26051642
[TBL] [Abstract][Full Text] [Related]
6. Probing Pharmaceutical Mixtures during Milling: The Potency of Low-Frequency Raman Spectroscopy in Identifying Disorder.
Walker G; Römann P; Poller B; Löbmann K; Grohganz H; Rooney JS; Huff GS; Smith GPS; Rades T; Gordon KC; Strachan CJ; Fraser-Miller SJ
Mol Pharm; 2017 Dec; 14(12):4675-4684. PubMed ID: 29091447
[TBL] [Abstract][Full Text] [Related]
7. The contribution of Raman spectroscopy to the analysis of phase transformations in pharmaceutical compounds.
Hédoux A; Guinet Y; Descamps M
Int J Pharm; 2011 Sep; 417(1-2):17-31. PubMed ID: 21256937
[TBL] [Abstract][Full Text] [Related]
8. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy.
Heinz A; Savolainen M; Rades T; Strachan CJ
Eur J Pharm Sci; 2007 Nov; 32(3):182-92. PubMed ID: 17716878
[TBL] [Abstract][Full Text] [Related]
9. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy.
Savolainen M; Kogermann K; Heinz A; Aaltonen J; Peltonen L; Strachan C; Yliruusi J
Eur J Pharm Biopharm; 2009 Jan; 71(1):71-9. PubMed ID: 18590816
[TBL] [Abstract][Full Text] [Related]
10. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
11. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Int J Pharm; 2011 Sep; 417(1-2):94-100. PubMed ID: 21182910
[TBL] [Abstract][Full Text] [Related]
12. Vibrational spectroscopic investigation of polymorphs and cocrystals of indomethacin.
Ali HR; Alhalaweh A; Velaga SP
Drug Dev Ind Pharm; 2013 May; 39(5):625-34. PubMed ID: 22480325
[TBL] [Abstract][Full Text] [Related]
13. Screening for differences in the amorphous state of indomethacin using multivariate visualization.
Savolainen M; Heinz A; Strachan C; Gordon KC; Yliruusi J; Rades T; Sandler N
Eur J Pharm Sci; 2007 Feb; 30(2):113-23. PubMed ID: 17169536
[TBL] [Abstract][Full Text] [Related]
14. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
15. A theoretical and spectroscopic study of gamma-crystalline and amorphous indometacin.
Strachan CJ; Rades T; Gordon KC
J Pharm Pharmacol; 2007 Feb; 59(2):261-9. PubMed ID: 17270079
[TBL] [Abstract][Full Text] [Related]
16. In situ monitoring of the crystalline state of active pharmaceutical ingredients during high-shear wet granulation using a low-frequency Raman probe.
Nomura K; Titapiwatanakun V; Hisada H; Koide T; Fukami T
Eur J Pharm Biopharm; 2020 Feb; 147():1-9. PubMed ID: 31841690
[TBL] [Abstract][Full Text] [Related]
17. Molecular orientation distributions in a biaxially oriented poly(L-lactic acid) film determined by polarized Raman spectroscopy.
Tanaka M; Young RJ
Biomacromolecules; 2006 Sep; 7(9):2575-82. PubMed ID: 16961320
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the Isothermal Dehydration of Crystalline Hydrates Using Low-Frequency Raman Spectroscopy.
Robert C; Fraser-Miller SJ; Be Rziņš KR; Okeyo PO; Rantanen J; Rades T; Gordon KC
Mol Pharm; 2021 Mar; 18(3):1264-1276. PubMed ID: 33406363
[TBL] [Abstract][Full Text] [Related]
19. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Eur J Pharm Biopharm; 2012 Feb; 80(2):459-64. PubMed ID: 22019529
[TBL] [Abstract][Full Text] [Related]
20. Spatial confinement can lead to increased stability of amorphous indomethacin.
Nielsen LH; Keller SS; Gordon KC; Boisen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2012 Jun; 81(2):418-25. PubMed ID: 22521331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
